The effective mode of action of clinical monoclonal antibodies (mAbs) that recognise cell surface receptors including CD6 is commonly cytotoxic depletion of cells. It is not clear how current therapeutic strategies to target CD6 perturb function.

2018年3月23日 · Although CD6 was one of the earliest “CD antigens” to be described, it is only recently that attention has refocused on the potential for CD6 as a treatment target in immune-mediated diseases....

2018年5月1日 · CD6 is a lymphocyte receptor selectively expressed on most T cells and some B cells. CD6 is involved in cell-to-cell contacts and modulation of adaptive immune responses. CD6 interacting partners include CD166/ALCAM, CD318 and certain PAMPS and DAMPS. CD6 is implicated in the pathogenesis of a variety of immune-mediated conditions.

2025年2月13日 · CD6 plays critical roles in lymphocyte activation, proliferation, and adhesion to antigen-presenting, epithelial, and cancer cells. CD6 is a risk gene for multiple autoimmune diseases, possibly related to its numerous roles in regulating CD4+T-cell responses. Additionally, CD6 is a potential target for cancer immunotherapy.

2018年12月17日 · CD6 favors thymocyte differentiation and maturation and is required for selection of thymocytes with high-avidity TCRs. CD6 is expressed at all stages of thymocyte development. Its expression is increased at the double positive stage in cells that are assigned to maturation (CD69 high). CD6 has an important role limiting the threshold for ...

CD6 is a signal-transducing receptor almost exclusively expressed by lymphocytes. CD6 was one of the first discovered lymphocyte surface receptors in the early 1980's, thanks to the development of monoclonal antibody (mAb) technology.

2015年8月4日 · We have solved the X-ray crystal structures of the three SRCR domains of CD6 and two N-terminal domains of CD166. This first structure of consecutive SRCR domains reveals a nonlinear organization. We characterized the binding sites on CD6 and CD166 and showed that a SNP in CD6 causes glycosylation that hinders the CD6/CD166 interaction.

2025年2月13日 · CD6 is a risk gene for multiple autoimmune diseases, possibly related to its numerous roles in regulating CD4+T-cell responses. Additionally, CD6 is a potential target for cancer immunotherapy. Here, we dissect the role of CD6 in the pathogenesis of more than 15 diseases and discuss recent data supporting the use of CD6-targeted therapy in humans.

2018年7月12日 · The scavenger-like lymphocyte receptor CD6 is a regulator of T cell functions, and is associated with autoimmune diseases. However, the specific contribution of CD6 to autoimmunity remains...

CD6 monoclonal antibodies (mAbs) specific for the membrane distal domain (domain 1) perturb CD6 function including itolizumab (Alzumab™), which has reached the clinic for treatment of autoimmune disease. We characterized molecular and functional properties of several CD6 mAbs including itolizumab to define potential mechanisms of action.